Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5275299
Max Phase: Preclinical
Molecular Formula: C46H53ClN6O7
Molecular Weight: 837.42
Associated Items:
ID: ALA5275299
Max Phase: Preclinical
Molecular Formula: C46H53ClN6O7
Molecular Weight: 837.42
Associated Items:
Canonical SMILES: CC1(C)[C@H](NC(=O)c2ccc(C(=O)NCCCCCCCCCCNc3cccc4c3C(=O)N(C3CCC(=O)NC3=O)C4=O)cc2)C(C)(C)[C@H]1Oc1ccc(C#N)c(Cl)c1
Standard InChI: InChI=1S/C46H53ClN6O7/c1-45(2)43(46(3,4)44(45)60-31-21-20-30(27-48)33(47)26-31)52-39(56)29-18-16-28(17-19-29)38(55)50-25-12-10-8-6-5-7-9-11-24-49-34-15-13-14-32-37(34)42(59)53(41(32)58)35-22-23-36(54)51-40(35)57/h13-21,26,35,43-44,49H,5-12,22-25H2,1-4H3,(H,50,55)(H,52,56)(H,51,54,57)/t35?,43-,44-
Standard InChI Key: QRQGVXVDQXIEQK-OBASXCCISA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 837.42 | Molecular Weight (Monoisotopic): 836.3664 | AlogP: 7.19 | #Rotatable Bonds: 18 |
Polar Surface Area: 186.80 | Molecular Species: NEUTRAL | HBA: 9 | HBD: 4 |
#RO5 Violations: 2 | HBA (Lipinski): 13 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 11.59 | CX Basic pKa: 2.20 | CX LogP: 7.45 | CX LogD: 7.45 |
Aromatic Rings: 3 | Heavy Atoms: 60 | QED Weighted: 0.08 | Np Likeness Score: -0.52 |
1. Han X, Wang C, Qin C, Xiang W, Fernandez-Salas E, Yang CY, Wang M, Zhao L, Xu T, Chinnaswamy K, Delproposto J, Stuckey J, Wang S.. (2019) Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer., 62 (2): [PMID:30629437] [10.1021/acs.jmedchem.8b01631] |
Source(1):